Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
300.1 GBX | +3.50% | +8.75% | +6.06% |
26/04 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
26/04 | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+6.06% | 3.08B | |
+25.72% | 661B | |
+26.74% | 566B | |
-6.56% | 352B | |
+20.42% | 332B | |
+3.01% | 283B | |
+13.43% | 231B | |
+4.70% | 200B | |
-9.41% | 195B | |
-5.10% | 145B |
- Stock Market
- Equities
- HCM Stock
- News HUTCHMED (China) Limited
- HUTCHMED (China) Initiates Bridging Study of Tazemetostat in Relapsed or Refractory Follicular Lymphoma Patients in China